View Older Stories View More Recent Stories

Jun 4, 2025 09:05AM BridgeBio Pharma (BBIO) PT Raised to $42 at BMO Capital
May 25, 2025 03:00PM Biotech stocks Q1 earnings review
May 19, 2025 12:37PM BridgeBio Pharma Inc. (BBIO): Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
May 13, 2025 07:31AM BridgeBio Pharma Inc. (BBIO): First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
Apr 30, 2025 03:25PM BridgeBio Pharma Inc. (BBIO) call put ratio 1.2 calls to 1 put with a focus on May calls and puts as share price up 4.5%
Apr 30, 2025 07:20AM BridgeBio Pharma (BBIO) PT Raised to $55 at Scotiabank
Apr 30, 2025 01:42AM BridgeBio Pharma Inc. (BBIO) Tops Q1 EPS by 3c
Apr 11, 2025 09:44AM Piper Sandler: 'What Biotech Names to Own in Market Volatility'
Apr 10, 2025 07:31AM Piper Sandler on BridgeBio Pharma (BBIO): 'Attruby Launch In Early Innings Looks Strong'
Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
Apr 1, 2025 06:41AM Raymond James Reiterates Outperform Rating on BridgeBio Pharma (BBIO)
Mar 31, 2025 10:00AM BridgeBio Pharma (BBIO) Reports Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Mar 31, 2025 04:15AM Redburn-Atlantic Starts BridgeBio Pharma (BBIO) at Buy
Mar 27, 2025 07:00AM BridgeBio Pharma (BBIO) Announces Beyonttra Approved in Japan to Treat ATTR-CM
Mar 17, 2025 04:01PM BridgeBio Pharma Inc. (BBIO) appoints Thomas Trimarchi as CFO
Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more
Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
Mar 10, 2025 08:02AM Deep Track Capital Sends Letter to Dynavax Technologies’ (DVAX) Board
Mar 6, 2025 09:05AM Cantor Fitzgerald Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
Feb 28, 2025 07:50AM BridgeBio Oncology Therapeutics to go Public via Merger with Helix Acquisition Cp II (HLXB)
Feb 24, 2025 04:11PM BridgeBio Pharma (BBIO) Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
Feb 21, 2025 07:14AM BridgeBio Pharma (BBIO) PT Raised to $52 at Scotiabank
Feb 20, 2025 07:40AM BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 27c
Feb 19, 2025 10:00AM Piper Sandler on BridgeBio Pharma (BBIO): 'Survey Suggests Strong Launch Dynamics For Attruby'
Feb 15, 2025 10:00PM Biotech Q4 earnings preview: Goldman Sachs
Feb 12, 2025 07:11AM BridgeBio Pharma (BBIO) PT Raised to $49 at Scotiabank
Feb 11, 2025 09:22AM BridgeBio Pharma Inc. (BBIO) Announces BEYONTTRA Approved by the European Commission to Treat ATTR-CM
Jan 13, 2025 11:00AM BridgeBio Pharma Inc. (BBIO) Announces Commercial Progress, Program Updates, and 2025 Milestones
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Dec 18, 2024 09:08AM Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO) Following Key Investor Debate
Dec 16, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
Dec 13, 2024 07:19AM BridgeBio Pharma's (BBIO) Acoramidis Receives Positive CHMP Opinion
Nov 25, 2024 09:18AM TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)
Nov 25, 2024 08:24AM BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)
Nov 25, 2024 08:12AM Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
Nov 25, 2024 07:13AM BridgeBio Pharma (BBIO): Attruby approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Nov 25, 2024 06:38AM BridgeBio Pharma (BBIO) PT Raised to $49 at H.C. Wainwright
Nov 22, 2024 04:09PM BridgeBio Pharma Inc. (BBIO) Halted, News Pending
Nov 12, 2024 04:34PM BridgeBio Pharma Inc. (BBIO) Tops Q3 EPS by 13c
Nov 5, 2024 07:30AM BridgeBio Pharma Inc. (BBIO) Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
Oct 24, 2024 10:53AM Citi Reiterates Buy Rating on BridgeBio Pharma (BBIO)
Oct 24, 2024 07:30AM BridgeBio (BBIO) Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
Oct 2, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
Sep 30, 2024 08:25AM BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)
Sep 30, 2024 07:51AM Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
Sep 30, 2024 07:32AM BridgeBio Pharma (BBIO) Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9
Sep 30, 2024 07:24AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
Sep 24, 2024 08:17AM BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)
Sep 17, 2024 07:31AM BridgeBio Pharma (BBIO) announces FDA has granted Breakthrough Therapy Designation to oral infigratinib
Sep 16, 2024 07:07AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
View More Recent Stories View Older Stories